Compare ASMB & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | EBS |
|---|---|---|
| Founded | 2005 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 411.1M |
| IPO Year | 2010 | 2006 |
| Metric | ASMB | EBS |
|---|---|---|
| Price | $28.45 | $8.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $44.20 | $12.00 |
| AVG Volume (30 Days) | 93.4K | ★ 663.9K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.78 | ★ 125.83 |
| EPS | N/A | ★ 0.93 |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | $638.39 | N/A |
| P/E Ratio | ★ N/A | $8.92 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.53 | $4.71 |
| 52 Week High | $39.71 | $14.06 |
| Indicator | ASMB | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 48.99 | 43.90 |
| Support Level | $27.10 | $7.73 |
| Resistance Level | $30.58 | $8.54 |
| Average True Range (ATR) | 1.38 | 0.35 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 44.63 | 24.61 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.